Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $317,066.20 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Sean Maduck sold 4,315 shares of the stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $73.48, for a total value of $317,066.20. Following the transaction, the insider owned 17,705 shares in the company, valued at $1,300,963.40. The trade was a 19.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Sean Maduck also recently made the following trade(s):

• On Friday, July 18th, Sean Maduck sold 473 shares of Corcept Therapeutics stock. The stock was sold at an average price of $73.44, for a total value of $34,737.12.
• On Tuesday, July 1st, Sean Maduck sold 205 shares of Corcept Therapeutics stock. The shares were sold at an average price of $73.45, for a total value of $15,057.25.
• On Monday, June 2nd, Sean Maduck sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $79.08, for a total transaction of $1,581,600.00.
• On Friday, May 2nd, Sean Maduck sold 26,554 shares of Corcept Therapeutics stock. The stock was sold at an average price of $72.23, for a total transaction of $1,917,995.42.

Corcept Therapeutics Stock Performance

NASDAQ:CORT traded down $0.74 during midday trading on Monday, reaching $70.12. 628,963 shares of the stock traded hands, compared to its average volume of 1,184,765. Corcept Therapeutics Incorporated has a 12 month low of $32.33 and a 12 month high of $117.33. The stock has a market capitalization of $7.44 billion, a P/E ratio of 60.45 and a beta of 0.15. The company has a fifty day moving average of $72.75 and a 200 day moving average of $67.35.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The firm had revenue of $157.21 million during the quarter, compared to analysts' expectations of $177.93 million. Corcept Therapeutics had a net margin of 19.33% and a return on equity of 20.40%. The company's quarterly revenue was up 7.1% compared to the same quarter last year. During the same period last year, the company posted $0.25 EPS. On average, analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on CORT. Wall Street Zen lowered shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. HC Wainwright dropped their price objective on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. Finally, Truist Financial set a $135.00 price target on Corcept Therapeutics in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Corcept Therapeutics has an average rating of "Moderate Buy" and an average target price of $138.25.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Corcept Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock valued at $509,726,000 after acquiring an additional 109,294 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Corcept Therapeutics by 3.7% in the first quarter. Parallel Advisors LLC now owns 3,972,416 shares of the biotechnology company's stock worth $453,729,000 after purchasing an additional 142,784 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Corcept Therapeutics by 2.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,136,510 shares of the biotechnology company's stock worth $243,708,000 after purchasing an additional 57,942 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Corcept Therapeutics by 4.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock valued at $82,889,000 after buying an additional 64,321 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Corcept Therapeutics by 12.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,376,881 shares of the biotechnology company's stock valued at $69,381,000 after buying an additional 153,100 shares during the period. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.